3 / 2018 / vol. 7
Kosmetologia Estetyczna
273
N
artykuł naukowy
dermatologia
Literatura
1.
Ali Z, Yousaf N, Larkin J. Melanoma epidemiology, biology and prognosis. European
Journal of Cancer 2013, vol. 11(2): 81-91.
2.
Green AC, Baade P, Coory M, Aitken JF, Smithers M. Population-based 20-year
survival among people diagnosed with thin melanomas in Queensland, Australia.
Journal of Clinical Oncology 2012, vol. 30(13): 1462-1467.
3.
Rastrelli M, Tropea S, Rossi CR, Alaibac M. Melanoma: Epidemiology, Risk Factors, Pa-
thogenesis, Diagnosis and Classification, [w:] In Vivo – International Journal of Expe-
rimental and Clinical Pathophysiology and Drug Research 2014, vol. 28(6): 1005-1012.
4.
Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer
incidence and mortality worldwide: Sources, methods and major patterns in GLO-
BOCAN 2012. International Journal of Cancer 2015, vol. 136(5): 359-386.
5.
Gajda M, Kaminska-Winciorek G. Do Not Let to Be Late: Overview of Reasons for
Melanoma Delayed Diagnosis. Asian Pacific Journal of Cancer Prevention 2014, vol.
15(9): 3873-3877.
6.
Pennello G, Devesa S, Gail M. Association of Surface Ultraviolet B Radiation Levels
with Melanoma and Nonmelanoma Skin Cancer in United States. Cancer Epidemio-
logy, Biomarkers and Prevention 2000, vol. 9: 291-297.
7.
Hałas P. Charakterystyka czerniaka oraz ocena poziomu wiedzy studentów na te-
mat czerniaka złośliwego. Kosmetologia Estetyczna 2017, vol. 6: 223-228.
8.
Green A, Autier P, Boniol M, Boyle P, Doré JF, Gandini S, et al. The association of use
of sunbeds with cutaneous malignant melanoma and other skin cancers: A syste-
matic review. International Journal of Cancer 2007, vol. 120(5): 1116-1122.
9.
Carolina A, Pereira F, Colosimo EA, Bittencourt FV, Julius A, Wainstein A, et al.
Prognostic factors for metastasis in cutaneous melanoma. Brazilian Annals of Der-
matology 2018, vol. 93: 19-26.
10.
Pollitt RA, Geller AC, Brooks DR, Johnson TM, Park ER, Swetter SM. Efficacy of
skin self-examination practices for early melanoma detection. Cancer Epidemiology,
Biomarkers nad Prevention 2009, vol. 18(11): 3018-3023.
11.
Titus LJ, Clough-Gorr K, Mackenzie TA, Perry A, Spencer SK, Weiss J, Abrahams-
-Gessel S, Ernstoff MS. Recent skin self-examination and doctor visits in relation to
melanoma risk and tumour depth. British Journal of Dermatol 2015, vol. 25(8): 713-724.
12.
Beardmore GL, Davis NC. Multiple primary cutaneous melanomas. Archives of
Dermatology 1975, vol. 111(5): 603-609.
13.
Psaty EL, Scope A, Halpern AC, Marghoob AA. Defining the patient at high risk for
melanoma. International Journal of Dermatol 2010, vol. 49(4): 362-376.
14.
Florell SR, Boucher KM, Garibotti G, Astle J, Kerber R, Mineau G, et al. Population-
-based analysis of prognostic factors and survival in familial melanoma. Journal of
Clinical Oncology 2005, vol. 23(28): 7168-7177.
15.
Hemminki K, Zhang H, Czene K. Familial and attributable risks in cutaneous mela-
noma: Effects of proband and age. Journal of Investigative Dermatology 2003, vol.
120(2): 217-223.
16.
Brenner AV, Lubin JH, Calista D, Landi MT. Instrumental measurements of skin co-
lor and skin ultraviolet light sensitivity and risk of cutaneous malignant melanoma:
A case-control study in an Italian population. American Journal of Epidemiology
2002, vol. 156(4): 353-362.
17.
Martin-Gorgojo A, Llinares M, Virós A, Requena C, Garcia-Casado Z, Traves V,
et al. Cutaneous melanoma primary site is linked to nevus density. Oncotarget 2017,
vol. 8(58): 98876-98886.
18.
Vogel RI, Ahmed RL, Nelson HH, Berwick M, Weinstock MA, Lazovich D. Exposure
to indoor tanning without burning and melanoma risk by sunburn history. Journal
of the National Cancer Institute 2014, vol. 106(7): 1-3.
19.
Nijsten TEC, Stern RS. The Increased Risk of Skin Cancer Is Persistent After Dis-
continuation of Psoralen+Ultraviolet A: A Cohort Study. Journal of Investigative
Dermatology 2003, vol. 121(2): 252-258.
20.
Hole DJ, Hunter JAA, Mackie RM, Clark J. Benign melanocytic naevi as a risk factor
for malignant melanoma. British Medical Journal 1986, vol. 292(6535): 1555-1559.
21.
Bristow IR, de Berker DA, Acland KM, Turner RJ, Bowling J. Clinical guidelines for
the recognition of melanoma of the foot and nail unit. Journal of Foot and Ankle
Research 2010, vol. 3(1): 25.
22.
Haneke E. Ungual melanoma – Controversies in diagnosis and treatment. Dermatol-
gic Therapy 2012, vol. 25(6): 510-524.
23.
Tiger JB, Habeshian KA, Barton DT, Brennick JB. Repigmentation of hair associated
with melanoma in situ of scalp. Journal of the American Academy of Dermatology
2014, vol. 71(4): 144-145.
24.
Rutkowski P, Wysocki PJ, Rutkowski P, Wysocki PJ, Nasierowska-Guttmejer A, Je-
ziorski A, et al. Cutaneous melanomas 2017, vol. 13(6): 241-258.
25.
Krzakowski M, Potemski P, Warzocha K, Wysocki P. Onkologia Kliniczna, Via Me-
dica, Gdańsk 2015: 838-855.
26.
Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, et al. Adju-
vant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. The New
England Journal of Medicine 2017, vol. 377(19): 1824-1835.
27.
Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, et al. Ad-
juvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. The New
England Journal of Medicine 2018, vol. 378(19): 1789-1801.
